At a glance
ClinicalIndex Comparison RecordN/ACompleted· 11 enrolled
Drug / intervention
Ranolazinedrug
Likely dose
Ranolazine 1000mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine
In Brief
A clinical study evaluating Ranolazine for Adenocarcinoma of the Prostate and 6 related conditions. Completed, enrolled 11 participants across 1 site.
Detailed Summary
This pilot clinical trial studies fludeoxyglucose F18 (FDG)-positron emission tomography (PET) in imaging patients with prostate cancer treated with ranolazine. Diagnostic procedures, such as FDG-PET, may help find prostate cancer and find out how far the disease has spread. Giving ranolazine may enhance FDG-PET imaging by increasing the amount of glucose available for uptake by the scan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Prostate, Bone Metastases, Soft Tissue Metastases, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartApr 2014
Primary CompletionOct 2016
Study CompletionApr 2018
TodayJul 2026
First PostedNov 25, 2013
Enrollment StartApr 7, 2014
Primary CompletionOct 8, 2016
Study CompletionApr 11, 2018
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 12.6 years ago
Interventions
Ranolazinedrug
1000mg given orally twice daily for 1 day (2 doses).